Immatics (IMTX) Competitors $5.64 +0.05 (+0.89%) As of 07/3/2025 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMTX vs. HCM, OGN, AMRX, MIRM, XENE, BHC, IBRX, GMTX, ARWR, and APLSShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include HUTCHMED (HCM), Organon & Co. (OGN), Amneal Pharmaceuticals (AMRX), Mirum Pharmaceuticals (MIRM), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Its Competitors HUTCHMED Organon & Co. Amneal Pharmaceuticals Mirum Pharmaceuticals Xenon Pharmaceuticals Bausch Health Cos ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals Immatics (NASDAQ:IMTX) and HUTCHMED (NASDAQ:HCM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations. Which has more volatility & risk, IMTX or HCM? Immatics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Do analysts prefer IMTX or HCM? Immatics currently has a consensus price target of $14.67, indicating a potential upside of 160.05%. HUTCHMED has a consensus price target of $19.00, indicating a potential upside of 19.54%. Given Immatics' stronger consensus rating and higher possible upside, research analysts clearly believe Immatics is more favorable than HUTCHMED.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is IMTX or HCM more profitable? HUTCHMED has a net margin of 0.00% compared to Immatics' net margin of -14.73%. HUTCHMED's return on equity of 0.00% beat Immatics' return on equity.Company Net Margins Return on Equity Return on Assets Immatics-14.73% -4.52% -3.34% HUTCHMED N/A N/A N/A Does the media refer more to IMTX or HCM? In the previous week, HUTCHMED had 3 more articles in the media than Immatics. MarketBeat recorded 3 mentions for HUTCHMED and 0 mentions for Immatics. Immatics' average media sentiment score of 0.00 equaled HUTCHMED'saverage media sentiment score. Company Overall Sentiment Immatics Neutral HUTCHMED Neutral Do institutionals and insiders believe in IMTX or HCM? 64.4% of Immatics shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 3.3% of Immatics shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable valuation & earnings, IMTX or HCM? HUTCHMED has higher revenue and earnings than Immatics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmatics$168.65M4.06$16.47M-$0.17-33.18HUTCHMED$630.20M4.40$37.73MN/AN/A SummaryHUTCHMED beats Immatics on 8 of the 14 factors compared between the two stocks. Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$694.05M$2.92B$5.55B$9.05BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-33.1721.5627.6120.23Price / Sales4.06278.31417.23118.52Price / Cash23.3742.7336.8958.10Price / Book1.107.518.035.67Net Income$16.47M-$55.14M$3.18B$249.21M7 Day Performance3.87%4.61%2.93%3.28%1 Month Performance-2.42%4.72%3.75%5.55%1 Year Performance-51.96%5.92%35.20%21.09% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics2.4518 of 5 stars$5.64+0.9%$14.67+160.0%-52.3%$694.05M$168.65M-33.17260HCMHUTCHMED1.3545 of 5 stars$15.05-0.3%$19.00+26.2%-9.3%$2.63B$630.20M0.001,811Positive NewsOGNOrganon & Co.4.8953 of 5 stars$9.68-1.8%$18.00+86.0%-50.4%$2.56B$6.40B3.364,000Trending NewsAMRXAmneal Pharmaceuticals3.7842 of 5 stars$8.09-0.5%$11.60+43.4%+26.8%$2.55B$2.79B-202.208,100High Trading VolumeMIRMMirum Pharmaceuticals3.7349 of 5 stars$50.89-0.4%$65.50+28.7%+47.4%$2.53B$336.89M-31.61140News CoverageXENEXenon Pharmaceuticals2.929 of 5 stars$31.30-3.4%$54.82+75.1%-3.9%$2.49B$9.43M-9.69210BHCBausch Health Cos3.1195 of 5 stars$6.68+3.4%$7.42+11.0%-2.8%$2.39B$9.63B-60.7320,700IBRXImmunityBio1.8594 of 5 stars$2.64-2.2%$12.25+364.0%-57.0%$2.38B$14.74M-4.55590Negative NewsGap UpGMTXGemini TherapeuticsN/A$54.50+0.7%N/A+23.2%$2.36BN/A-54.5030High Trading VolumeARWRArrowhead Pharmaceuticals3.9458 of 5 stars$15.80-1.7%$43.71+176.7%-33.1%$2.22B$3.55M-11.29400APLSApellis Pharmaceuticals4.428 of 5 stars$17.31-0.7%$40.05+131.4%-49.2%$2.19B$781.37M-9.67770Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies HUTCHMED Competitors Organon & Co. Competitors Amneal Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Bausch Health Cos Competitors ImmunityBio Competitors Gemini Therapeutics Competitors Arrowhead Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
